article · Journal of Biomolecular Structure and Dynamics
Yassir BoulaamaneMonoamine oxidase B serves as a key drug target for treating Parkinson's disease, but existing treatments cause undesirable side effects. To understand why specific coumarin molecules preferentially block this enzyme over monoamine oxidase A, researchers modelled three pairs of coumarin isomers substituted at either the sixth or seventh position. Computational docking showed that the monoamine oxidase B-selective sixth-position isomers shared a specific pi-pi stacking interaction with the Tyr-326 amino acid residue. Subsequent molecular dynamics simulations extending over 100 nanoseconds examined the stability of these protein-ligand complexes. While the seventh-position isomer remained stable in both enzyme forms, the selective sixth-position isomer proved unstable when bound to monoamine oxidase A, potentially because of interference from a bulky phenylalanine residue. These computational insights help explain the molecular basis of selectivity and offer guidance for optimising coumarin derivatives as future antiparkinsonian therapies.
Current medications targeting monoamine oxidase B often suffer from side effects linked to a lack of selectivity between enzyme types. Revealing how chemical arrangements influence selective binding enables researchers to design targeted compounds more precisely. This computational understanding helps clear a pathway towards safer, more effective pharmaceutical treatments for individuals living with Parkinson's disease.
This research provides early-stage computational insights for pharmaceutical drug discovery teams seeking to design selective antiparkinsonian therapies. By identifying specific structural interactions that exclude monoamine oxidase A binding, the findings can inform medicinal chemistry programmes during lead optimisation. The work remains at an early computational stage, requiring physical synthesis, in vitro validation, and preclinical testing before any direct clinical or commercial drug product can emerge.
AI-generated from the published abstract. Always read the original work before citing.
Monoamine Oxidase B is considered a successful target for developing antiparkinsonian drugs. Due to the side effects of current MAO-B inhibitors, there's an urgent need for novel potent and highly selective MAO-B inhibitors. A recent study has shown that coumarins tend to be more selective towards MAO-B than MAO-A when connected to a hex-5-ynyloxy chain at position 6 in contrast to their C7-isomers. The present study describes the mode of interaction of the C6 and C7-substituted coumarin isomers characterized by their difference in selectivity towards MAO-B through molecular docking and molecular dynamics simulations in an effort to elucidate the structural components and molecular interactions that may be responsible for MAO-B selectivity. Three isomeric coumarin pairs connected to ether chain at position 6 or 7 were taken from the literature and modelled according to their IUPAC nomenclature. Molecular docking study revealed one π- π stacking interaction with Tyr-326 in common between the selective coumarin C6-isomers. Resulting complexes of one isomeric coumarin pair that displayed the highest selectivity shift towards MAO-B were subject to 100 ns molecular dynamics simulations study to analyze the stability of the docked complexes. Molecular dynamics revealed that the C7-isomer is relatively stable in both MAO isoforms through the simulation duration, whereas the C6-isomer deemed unstable for MAO-A which may be due to the bulky Phe-208 residue in MAO-A. Our results might be applied for further development and optimization of coumarin derivatives into a successful drug against Parkinson's disease.Communicated by Ramaswamy H. Sarma.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/07391102.2022.2033643
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
